The novel drug known as Tildrakizumab is currently under review by the US FDA and the European Medicines Agency (EMA). The value of the contract is about $55.5 million.Sun Pharmaceutical signs agreement with Samsung BioLogics for psoriasis drug
The novel drug known as Tildrakizumab is currently under review by the US FDA and the European Medicines Agency (EMA). The value of the contract is about $55.5 million.
0 коммент.:
Отправить комментарий